Published January 2021
| Version v1
Journal article
Upfront surgery or definitive radiotherapy for p16+ oropharyngeal cancer. A GETTEC multicentric study
Creators
- Culié, Dorian
- Schiappa, Renaud
- Modesto, Anouchka
- Viotti, Julien
- Chamorey, Emmanuel
- Dassonville, Olivier
- Poissonnet, Gilles
- Bizeau, Alain
- Vergez, Sebastien
- Dupret-Bories, Agnes
- Fakhry, Nicolas
- Santini, Laure
- Lallemant, Benjamin
- Chambon, Guillaume
- Sudaka, Anne
- Peyrade, Frederic
- Saada-Bouzid, Esma
- Benezery, Karen
- Jourdan-Soulier, Florence
- Chapel, Françoise
- Ramay, Anne Sophie
- Roger, Pascal
- Galissier, Thibault
- Coste, Valérie
- Ben Lakdar, Aicha
- Guerlain, Joanne
- Mirghani, Haitham
- Gorphe, Phillipe
- Guelfucci, Bruno
- Garrel, Renaud
- Temam, Stephane
- Bozec, Alexandre
Contributors
Others:
- Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL) ; UNICANCER-Université Côte d'Azur (UCA)
- Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037) ; Université Toulouse III - Paul Sabatier (UT3) ; Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Centre Hospitalier Intercommunal Toulon-La Seyne sur Mer - Hôpital Sainte-Musse
- Assistance Publique - Hôpitaux de Marseille (APHM)
- Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)
- Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM) ; CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)
- Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)
- Pathogenesis and Control of Chronic and Emerging Infections (PCCEI) ; Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Université des Antilles (UA)-Etablissement français du don du sang [Montpellier]
- Institut Gustave Roussy (IGR)
- Département de cancérologie cervico-faciale [Gustave Roussy] (CCF) ; Institut Gustave Roussy (IGR)
- Hôpital Européen Georges Pompidou [APHP] (HEGP) ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)
- Université de Montpellier (UM)
Description
Background: The aim of this study was to assess the impact of the initial therapeutic strategy on oncologic outcomes in patients with HPV-positive OPSCC.Methods: All p16-positive OPSCCs treated from 2009 to 2014 in 7 centers were retrospectively included and classified according to the therapeutic strategy: surgical strategy (surgery ± adjuvant radiotherapy and chemotherapy) vs. non-surgical strategy (definitive radiotherapy ± chemotherapy). Univariate, multivariate propensity score matching analyses were performed to compare overall (OS), disease-specific (DSS) and recurrence-free survival (RFS).Results: 382 patients were included (surgical group: 144; non-surgical group: 238). Five-year OS, DSS and RFS were 89.2, 96.8 and 83.9% in the surgical group and 84.2, 87.1 and 70.4% in the non-surgical group, respectively. These differences were statistically significant for DSS and RFS after multivariate analysis, but only for RFS after propensity score matching analysis.Conclusion: In p16+ OPSCC patients, upfront surgery results in higher RFS than definitive radiotherapy ± chemotherapy but does not impact OS.
Abstract
International audienceAdditional details
Identifiers
- URL
- https://hal.umontpellier.fr/hal-03166902
- URN
- urn:oai:HAL:hal-03166902v1